Search company, investor...

Stage

Series A | Alive

Total Raised

$16.37M

Last Raised

$10.66M | 6 yrs ago

About Biosceptre International

Biosceptre International is a company focused on the development of innovative cancer therapies, operating within the biotechnology and healthcare sectors. The company's main offerings include the development of a multi-targeted universal CAR T system, which is designed to improve the lives of cancer patients by potentially treating a wide range of malignancies. Biosceptre primarily serves the healthcare industry, specifically the cancer treatment sector. It is based in Cambridge, England.

Headquarters Location

Jonas Webb Building, Babraham Research Campus Babraham

Cambridge, England, CB22 3AT,

United Kingdom

+ 44 1223 496 090

Loading...

Loading...

Biosceptre International Patents

Biosceptre International has filed 17 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/7/2015

4/17/2018

Ion channels, G protein coupled receptors, Cell signaling, Adenosine receptor antagonists, Integral membrane proteins

Grant

Application Date

10/7/2015

Grant Date

4/17/2018

Title

Related Topics

Ion channels, G protein coupled receptors, Cell signaling, Adenosine receptor antagonists, Integral membrane proteins

Status

Grant

Latest Biosceptre International News

Biosceptre International Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250

Sep 5, 2018

12:35 EDT 5 Sep 2018 | BioPortfolio Reports Summary Biosceptre International Ltd Biosceptre is a biotechnology company that develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer . The company develops imaging technologies to detect and monitor cancer. Biosceptre's diagnostic products are used for the detection of various cancer tissues, and treatment of various cancers in humans and other mammals. The company has a series of clinical product development programs including polyclonal antibody, domain antibodies and topical formulation to treat basal cell carcinoma and other skin cancers. It also develops diagnostics and a line of veterinary therapeutic products. The company has operations in the UK, Australia, and the US. Biosceptre is headquartered in North Ryde, New South Wales, Australia. Biosceptre International Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Biosceptre International Frequently Asked Questions (FAQ)

  • Where is Biosceptre International's headquarters?

    Biosceptre International's headquarters is located at Jonas Webb Building, Babraham Research Campus, Cambridge.

  • What is Biosceptre International's latest funding round?

    Biosceptre International's latest funding round is Series A.

  • How much did Biosceptre International raise?

    Biosceptre International raised a total of $16.37M.

  • Who are the investors of Biosceptre International?

    Investors of Biosceptre International include Tuspark S & T.

  • Who are Biosceptre International's competitors?

    Competitors of Biosceptre International include Longevica, Abeome, ADV Bioscience, Keryx Biopharmaceuticals, Threshold Pharmaceuticals and 7 more.

Loading...

Compare Biosceptre International to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

I
Institute of Forest Biotechnology

The institute works for societal, ecological, and economic benefits from the appropriate uses of biotechnology in forestry worldwide. The company's cornerstone programs are Heritage Trees, Ecological Ramifications, Societal Issues and Outreach.

A
Agennix

Agennix is a company focused on the discovery and development of next-generation antibodies within the biotechnology sector. The company offers a range of scientific research products including antibodies, ELISA kits, recombinant proteins, PCR quality control materials, and various kits for DNA and RNA library preparation, PCR, and cell culture. These products are designed to support researchers in biology, chemistry, pharmacology, and other scientific fields. It is based in Houston, Texas.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

S
Spaltudaq

Spaltudaq is a company that specializes in the construction industry, with a focus on roofing services. The company offers a range of services including roof installation, roof replacement, and roof repair, catering to both residential and commercial needs. These services are designed to ensure the durability and longevity of roofing systems, providing protection and security for buildings. It was founded in 2004 and is based in Seattle, Washington.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.